Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 21:38:13时区推断·⟳ 抓取 21:38:55·⚡ 决策 07-23 21:43:47 +4m52s·95.9 天前
Labcorp触及293.92美元52周高点并披露多项近况
正文包括52周高点、0.72美元季度股息、ColoSense和应用集成等近况，但未给出新的订单、覆盖量或业绩增量。
📄 原文Investing.com↗ 原文
Labcorp Holdings Inc stock hits 52-week high at 293.92 USD
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea Labcorp Holdings Inc stock reached a 52-week…
不做 Labcorp（LH.US）
主要是股价高点和旧近况汇总，缺少新增可量化催化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 low · price-in 风险 high ↗
消息传播链
- 报道Labcorp触及52周高点，并汇总股息、ColoSense、DPYD检测、MyLabcorp和Epic合作等近况。市场反应:LH.US现价295.17美元，较前收+4.87%。
关键理由
- 正文包括52周高点、0.72美元季度股息、ColoSense和应用集成等近况，但未给出新的订单、覆盖量或业绩增量。
主要风险
- LH.US当日已上涨4.87%，临近财报前的价格里程碑不适合作为独立催化追多。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 2,428 字
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea
Labcorp Holdings Inc stock reached a 52-week high, hitting a price of $293.92. The stock has since climbed to $296.17, with a 1-year total return of 13.54%. This milestone reflects a positive trajectory, supported by a low P/E ratio of 24.83 and an attractive PEG ratio of 0.81, suggesting the stock trades at a discount relative to its near-term earnings growth potential. The achievement of this 52-week high underscores investor confidence and market optimism surrounding Labcorp’s performance and future prospects. According to LH">InvestingPro analysis, the stock is trading near its Fair Value, with the platform’s Financial Health Score rated as "GREAT." InvestingPro offers 5 additional exclusive tips for LH, plus access to comprehensive Pro Research Reports covering this and 1,400+ other US equities. As the company continues to navigate the healthcare landscape with earnings just 7 days away, this upward trend in stock price highlights its resilience and potential for continued growth.
In other recent news, Labcorp has announced several key developments. The company declared a quarterly cash dividend of $0.72 per share, payable on September 11, 2026, to stockholders of record as of August 28, 2026. Labcorp also launched ColoSense, an FDA-approved at-home colorectal cancer screening test, which is the first of its kind using RNA technology. This test is now covered for eligible Medicare and Medicare Advantage beneficiaries. Additionally, Labcorp expanded its DPYD Genotyping test, which identifies cancer patients at risk for severe side effects from fluoropyrimidine chemotherapy, now including all DPYD Tier 1 and Tier 2 variants.
Furthermore, Labcorp introduced MyLabcorp, a mobile app powered by artificial intelligence, designed to help users track and interpret their laboratory test results. The app provides personalized explanations and identifies patterns using OpenAI models. In another move, Labcorp expanded its collaboration with Epic, integrating its full test menu into Epic’s Aura platform, allowing health systems to access Labcorp’s diagnostic tests within their existing workflows. These recent developments highlight Labcorp’s ongoing efforts to enhance healthcare accessibility and patient safety.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Labcorp Holdings Inc stock reached a 52-week high, hitting a price of $293.92. The stock has since climbed to $296.17, with a 1-year total return of 13.54%. This milestone reflects a positive trajectory, supported by a low P/E ratio of 24.83 and an attractive PEG ratio of 0.81, suggesting the stock trades at a discount relative to its near-term earnings growth potential. The achievement of this 52-week high underscores investor confidence and market optimism surrounding Labcorp’s performance and future prospects. According to LH">InvestingPro analysis, the stock is trading near its Fair Value, with the platform’s Financial Health Score rated as "GREAT." InvestingPro offers 5 additional exclusive tips for LH, plus access to comprehensive Pro Research Reports covering this and 1,400+ other US equities. As the company continues to navigate the healthcare landscape with earnings just 7 days away, this upward trend in stock price highlights its resilience and potential for continued growth.
In other recent news, Labcorp has announced several key developments. The company declared a quarterly cash dividend of $0.72 per share, payable on September 11, 2026, to stockholders of record as of August 28, 2026. Labcorp also launched ColoSense, an FDA-approved at-home colorectal cancer screening test, which is the first of its kind using RNA technology. This test is now covered for eligible Medicare and Medicare Advantage beneficiaries. Additionally, Labcorp expanded its DPYD Genotyping test, which identifies cancer patients at risk for severe side effects from fluoropyrimidine chemotherapy, now including all DPYD Tier 1 and Tier 2 variants.
Furthermore, Labcorp introduced MyLabcorp, a mobile app powered by artificial intelligence, designed to help users track and interpret their laboratory test results. The app provides personalized explanations and identifies patterns using OpenAI models. In another move, Labcorp expanded its collaboration with Epic, integrating its full test menu into Epic’s Aura platform, allowing health systems to access Labcorp’s diagnostic tests within their existing workflows. These recent developments highlight Labcorp’s ongoing efforts to enhance healthcare accessibility and patient safety.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。